Effect of Prontosan Wound Irrigation Solution on Venous Ulcers
Study Details
Study Description
Brief Summary
Objective:
To evaluate the efficacy and safety of Prontosan® Wound Irrigation Solution in the treatment of hard-to-heal venous leg ulcers compared to wound irrigation with saline solution
Methodology:
Randomised, controlled multi-centre, prospective clinical trial
Planned number of subjects:
20 patients in experimental group (Prontosan® Wound Irrigation Solution) 8 patients in control group (wound irrigation with saline)
Products under investigation:
Prontosan® Wound Irrigation Solution
Study Duration:
3-4 weeks
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Investigational product, dose and administration:
Prontosan® Wound Irrigation Solution (experimental group) and saline solution (control group) will be applied at inclusion and reapplied after dressing changes.
The treatment scheme is as follows:
- Prontosan® Wound Irrigation Solution (experimental group):
-
cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the immediate wound in the form of a moist compress and removed after approximately 15 minutes;
-
placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;
-
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
- Saline (control group):
-
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
-
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
-
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Dressings will be changed and the treatment procedure will be repeated in the clinic 2x/weekly or more. The efficacy of the treatment procedure will be evaluated on the basis of a 2 week observation period.
Treatment efficacy assessment:
-
Assessment of clinical signs and symptoms at entry to the study and after one and two weeks.
-
Quantitative and qualitative microbiological analysis at entry to the study and after two weeks.
-
Wound planimetry using PictZar® CDM at entry to the study and after two weeks.
Primary aim:
- clinical signs assessed by:
-
reduction of slough and necrotic tissue
-
control of exudate
-
presence of granulation tissue
-
reduction of inflammatory signs (surrounding skin)
-
reduction in wound size (assessed by wound planimetry)
-
reduction of bacterial load (quantitative and qualitative microbiological
Secondary aim:
- tolerance and safety assessment:
-
adverse drug reaction
-
adverse events
-
early withdrawal from the study
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Prontosan wound irrigation solution Prontosan® Wound Irrigation Solution (experimental group): cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system). |
Device: Prontosan wound irrigation solution
Prontosan® Wound Irrigation Solution (experimental group):
• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound
Saline (control group):
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Other Names:
|
Placebo Comparator: Saline irrigation (standard care control) Saline (control group): cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes; placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline; fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system). |
Device: Prontosan wound irrigation solution
Prontosan® Wound Irrigation Solution (experimental group):
• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound
Saline (control group):
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Reduction of bacterial burden (quantitative bacteriology) Reduction in slough and necrotic tissue (clinical score) Amount and quality of granulation tissue (clinical score) Exudate type and amount (clinical score) [weekly]
Secondary Outcome Measures
- Adverse device effect (s) Adverse events [volunteered at any time or during weekly evaluation visits]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
males and females aged at least 18 with wounds of venous aetiology (documented by targeted exams) located in the lower limbs
-
Ankle Brachial Index (ABI) ≥ 0.7
-
patients who have not had an antimicrobial (systemic antibiotic or topical antiseptic) over the 30 days before joining the study
Exclusion Criteria:
Exclusion criteria
-
age below 18 years
-
presence of clinical infection, or current use of antiseptics or antibiotics
-
chronic wounds of long duration (>30cm2 and >1 year duration)
-
involvement in other wound related trials within the past 30 days
-
sensitivity to any of the components of Prontosan® or dressing material
-
intolerance to compression therapy
-
active osteomyelitis in the ulceration area
-
active rheumatoid arthritis (RA) requiring any immunosuppressive therapy
-
collagen vascular disease active treated with steroids
-
chronic diseases that could impact the course of the study (malicious cancer, TB, AIDS, mental illnesses)
-
plasma protein below 4 g/dl
-
anaemia: haemoglobin below 10 g/dl
-
both, controlled and uncontrolled diabetics (type 1 or 2)
-
patients on any rheological agents (not including aspirin)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Calvary hospital center for curative and palliative wound care | Bronx | New York | United States | 10461 |
Sponsors and Collaborators
- Calvary Hospital, Bronx, NY
- B. Braun Medical SA
Investigators
- Principal Investigator: Oscar M Alvarez, PhD, Calvary Hospital, Wound Care
- Study Director: Martin Wendelken, RN, DPM, Calvary Hospital, Wound Care
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OPM-I-H-0902